To order this detailed 500+ page report, please visit this -https://www.rootsanalysis.com/reports/view_document/stem-cells-market/296.html
Key Inclusions
§ A detailed assessmentof the current market landscape featuring over 280 stem cell-based therapiesapproved / under clinical development, including information on drug / therapydeveloper(s) (such as year of establishment, company size and location of headquarters),phase of development (marketed, phase III, phase II, phase I), source of stemcells (allogeneic and autologous), origin of stem cells (adult and embryonic),type of stem cells (hematopoietic, mesenchymal, progenitor and others), stemcell lineage (amniotic fluid, adipose tissue, bone marrow, cardiosphere,chondrocytes, corneal tissue, cord blood, dental pulp, neural tissue placenta, peripheral blood, stromalcells and others), stem cell potency(multipotent and pluripotent), target indication(s), key therapeutic area(s),route of administration (intravenous, intramuscular, intraarticular,intramyocardial, intracoronary, intrathecal and others), and information onnumber of stem cells, special drug / therapy designation (if any), commercialgeographical rights. In addition, information on the various technologyplatforms being actively used for the development of stem cell therapies hasbeen provided.
§ Identification ofcontemporary market trends, depicted using five schematic representations, whichinclude [A] a tree map representation of the various industry players involvedin the development of stem cell therapies, distributed on the basis of thetarget therapeutic areas of pipeline candidates and size of the companies(small, mid-sized and large companies), [B] a schematic world maprepresentation, highlighting the geographical locations of various industryplayers, [C] a bubble analysis comparing the leading players engaged in thegeneration of stem cell therapies, on the basis of parameters such as pipelinestrength (based on the number of therapy candidates developed by a particularcompany, across different phases of development), number of target indicationsand the size of the developer company, [D] an insightful grid analysis,highlighting the distribution of therapy candidates on the basis of phase ofdevelopment, source of stem cell and target therapeutic areas, and [E] aninformative heptagon representation, highlighting the distribution of marketed/ clinical stem cell therapies across popular target therapeutic areas (basedon the number of therapy candidates across each target therapeutic areas).
§ Detailed profiles ofthe key industry players engaged in the development of stem cell-basedtherapies, featuring a brief overview of the company (such as year ofestablishment, company size, location of headquarters, key members of theexecutive team and financial information (if available)), details of theirrespective product portfolio and an informed future outlook.
§ An assessment of over20 commonly targeted therapeutic indications and details of stem cell-basedtherapies being developed to treat the same conditions, highlighting diseasespecific epidemiological facts, contemporary methods of diagnosis, andcurrently available treatment options and their side-effects.
§ A detailedproprietary 2×2 representation that was developed to assess the current marketscenario (in terms of existing competition and growth opportunities) acrossemerging and established market segments.
§ An in-depth analysisof more than 1,500 grants that have been awarded to research institutes engagedin stem cell therapy-related projects, in the period between 2015 and 2019(till November), including analysis based on important parameters, such as yearof grant award, amount awarded, administration institute, funding institutecenter, funding institute center, support period, spending categorization,funding mechanism, grant type, responsible study section, focus area, prominentprogram officers, and type of recipient organizations. It also features adetailed analysis based on the types of stem cell (based on origin, source,potency and lineage) and therapeutic areas, along with a multivariate grantattractiveness analysis based on parameters, such as amount awarded, supportperiod, grant type, number of indications under investigation.
§ A detailed clinicaltrial analysis on more than 540 completed, ongoing and planned studies ofvarious stem cell therapies, highlighting prevalent trends across variousrelevant parameters, such as current trial status, trial registration year,phase of development, study design, leading industry sponsors (in terms ofnumber of trials conducted), study focus, type of stem cells, targetindication(s), target therapeutic area(s), enrolled patient population andregional distribution of trials.
§ A review of the keyaspects related to the manufacturing of stem cell therapies, including [A] adetailed discussion on processes and protocols, highlighting the need tooutsource various aspects of stem cell therapy development and manufacturingoperations, [B] an assessment of the current market landscape of contractmanufacturers, providing information on stem cell-focused service providers(such as year of establishment, company size, location of headquarters andmanufacturing facilities), scale of stem cell manufacturing (commercial,clinician and preclinical), services offered in addition to manufacturing(culture development / set up, stem cell identification / validation, stem cellbanking, regulatory consultancy, fill / finish, cryopreservation and stem celllogistics), source of stem cells(allogeneic and autologous), and origin of stem cells (adult and embryonic),[C] an insightful Harvey ball analysis to identify the key performance indicators/ key considerations that industry stakeholders are likely to take intoconsideration while selecting a suitable CMO / CRO partner.
§ A detailed market gapanalysis in order to develop a realistic understanding of the demand and supplydynamics within this field, comparing both clinical and commercial capabilitiesof therapy developers and the availability and capabilities of contractmanufacturers, across different geographies.
§ An elaboratediscussion on the various strategies that can be adopted by stem cell therapydevelopers across different stages of product development and commercialization(prior to product launch, post-marketing, and near patent expiry), and the keystrategies that have been adopted by drug developers for the commercializationof their proprietary product candidates.
§ An analysis ofcontemporary trends, as observed on the Google Trends portal, for the period2015-2019 and insights from the recent news articles related to stem celltherapies indicating the increasing popularity of this upcoming field ofresearch.
The report also features the likelydistribution of the current and forecasted opportunity across important marketsegments, mentioned below:
§ Sourceof stem cell
§ Allogeneic
§ Autologous
§ Originof stem cell
§ Adult
§ Embryonic
§ Type of stem cell
§ Hematopoietic
§ Mesenchymal
§ Progenitor
§ Others
§ Lineageof stem cell
§ AdiposeTissue
§ BoneMarrow
§ CordBlood
§ Others
§ Routeof Administration
§ Intraarticular
§ Intracoronary
§ Intramuscular
§ Intramyocardial
§ Intrathecal
§ Intravenous
§ SurgicalImplantations
§ Others
§ TherapeuticArea
§ Autoimmune/ Inflammatory Disorder
§ CardiovascularDisorders
§ MetabolicDisorder
§ MusculoskeletalDisorders
§ OncologicalDisorders
§ NeurologicalDisorders
§ OphthalmicDisorders
§ Others
§ EndUsers
§ AmbulatorySurgery Centers
§ Hospitals
§ SpecialtyClinics
§ KeyGeographies
§ NorthAmerica
§ Europe
- Asia-Pacific and Rest of the World
The report includesdetailed transcripts of discussions held with the following experts:
§ WilliamL Rust (Founder and Chief Executive Officer, Seraxis)
§ XuejunHuang Parsons (Chief Executive Officer, Xcelthera)
§ MichelRevel (Co-Founder and Chief Scientist, Kadimastem)and Galit Mazooz-Perlmuter (Director, Business Development, Kadimastem)
§ KikuoYasui (Director and Chief Operating Officer, Heartseed)
§ GustavSteinhoff (Director and Chairman, Department of Cardiac Surgery, University ofRostock)
§ GillesDevillers (President, Bio Elpida)
§ FionaBellot (Business Development Manager, Roslin Cell Therapies)
§ DavidMckenna (Professor and American Red Cross Chair in Transfusion Medicine, University ofMinnesota)
§ BrianDattilo (Manager of Business Development, Waisman Biomanufacturing)
§ MathildeGirard (Department Leader, Cell Therapy Innovation and Development, YposKesi)
To request sample pages, please visit this -https://www.rootsanalysis.com/reports/296/request-sample.html
Key Questions Answered
§ Who are the leading developers of stem cell therapies?
§ Whichtypes of clinical conditions can be treated using stem cell therapies?
§ Whichcell lineages and types of stem cells are commonly used for therapydevelopment?
§ Whatkind of key commercialization strategies are being used by stem cell therapydevelopers?
§ Whoare the key contract service providers engaged in this domain?
§ How is the current and future market opportunity likely tobe distributed across key market segments?
You may also beinterested in the following titles:
1. Stem Cell TherapyContract Manufacturing Market, 2019-2030
2. Antibody DrugConjugatesMarket (5th Edition), 2019-2030
3. Cell and AdvancedTherapies Supply Chain Management Market, 2019-2030: Focus on TechnologicalSolutions
4. Global T-Cell (CAR-T, TCR,and TIL) Therapy Market (4th Edition), 2019 – 2030
Contact Us
Gaurav Chaudhary
+1 (415) 800 3415
gaurav.chaudhary@rootsanalysis.com
